IL-17 Inhibition in Spondyloarthritis: A Targeted Approach in Psoriatic Arthritis - European Medical Journal
×

Browse

IL-17 Inhibition in Spondyloarthritis: A Targeted Approach in Psoriatic Arthritis

| Download as | PDF
Chairpeople:
Philip Mease1
Speakers:
Erik Lubberts,2 Iain McInnes,3 Désirée van der Heijde4
Disclosure:

Philip Mease has received research grants, consultation fees and/or speaker honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB; Erik Lubberts has received support from Novartis, Roche, Janssen, AbbVie, NTRC, Ensemble Therapeutics Group, and Pieris AG; Iain McInnes has received research funding and honoraria from Janssen, Eli Lilly, Amgen, Pfizer, Bristol-Myers Squibb, and Novartis; Désirée van der Heijde has received consulting fees and/or research grants from AbbVie, Amgen, AstraZeneca, Augurex, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli Lilly, Galapagos, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, UCB, and Vertex, and is a director of Imaging Rheumatology BV.

Acknowledgements:

Writing assistance was provided by Dr Jill Powell, apothecom scopemedical Ltd.

Support:

The publication of this article was funded by Novartis. The views and opinions expressed are those of the authors and not necessarily of Novartis.

Citation
EMJ Rheumatol. ;2[1]:55-64.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Prof Philip Mease introduced psoriatic arthritis (PsA) with a particular emphasis on disease symptoms and an update on the status of current disease management. Erik Lubberts described the interleukin (IL)-17 pathway and its role in the pathogenesis of PsA. Prof Iain McInnes reviewed the clinical evidence for the efficacy of IL-17 inhibition in PsA. Prof Désirée van der Heijde brought the symposium to a close with a presentation on the clinical impact of joint structural damage and strategies for its prevention in PsA.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the pdf above.